Back to search results
NCT06491927

Long Term Follow-up for RGX-202

Enrolling by Invitation
Not specifiedAll AgesObservational
REGENXBIO Inc.
~66 participants
Updated 2026-03-24 on ClinicalTrials.gov
What's tested:No Intervention

At a glance

Recruiting sites
0 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Evaluation of long-term safety of RGX-202
Measured over Baseline, 5 years inclusive of parent study

Conditions

Duchenne Muscular Dystrophy

Explore related trials

Duchenne Muscular DystrophyDystrophin

NCT06491927

Where you'd take part

This study runs at 5 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinoisno site contact published

  • Arkansas Children's Hospital

    Little Rock, Arkansasno site contact published

  • Stanford School of Medicine /Division of Neuromuscular Medicine

    Palo Alto, Californiano site contact published

  • The University of Texas Southwestern Medical Center

    Dallas, Texasno site contact published

  • Virginia Commonwealth University

    Richmond, Virginiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

The parent(s) or legal guardian(s) of the participant has/(have) provided written informed consent and (where applicable) Health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been explained, prior to any research-related procedures; and, where applicable, the minor participant has provided written or verbal assent according to local requirements.
Must have undergone evaluation in a previous clinical study following a single IV infusion of RGX-202 for the treatment of DMD and either completed or withdrawn early from that study.
Participant and parent(s)/legal guardian(s) are willing and able to comply with scheduled visits, and study procedures.
Sexually active participants must be willing to use a medically accepted method of contraception from the time of the screening visit through 5 years after RGX-202 administration.

What this trial measures

  • Evaluation of long-term safety of RGX-202Baseline, 5 years inclusive of parent study

    Incidences of AEs and SAEs over time